Importance of glycemic control on the course of glomerular filtration rate in type 2 diabetes with hypertension and microalbuminuria under tight blood pressure control

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 18, Issue 9, 2008, Pages 632-638

  Thomaseth, Karl ^a   Pacini, Giovanni ^a   Morelli, Patrizia ^b   Tonolo, Giancarlo ^c   Nosadini, Romano ^c  

^a CNR   (Italy)

^b Bayer SpA Italy   (Italy)

^c UNIVERSITY OF SASSARI   (Italy)

Author keywords

Glomerular filtration rate; HbA1c; Hypertension; Microalbuminuria; Type 2 diabetes

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; ALBUMINURIA; ARTICLE; BLOOD; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY;

ADULT; AGED; ALBUMINURIA; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; MALE; MIDDLE AGED;

EID: 54049147443     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2007.05.006     Document Type: Article

References (26)

1. US Renal Data System. USDRS 1999 annual data report. National Institute of Diabetes and Digestive and Kidney Diseases (1999), National Institutes of Health, Bethesda, Md. http://www.usrds.org/adr_1999.htm 25-38,
2. Mogensen C.E., Keane W.F., Bennett P.H., Jerums G., Parving H.H., Passa P., et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 346 (1995) 1040-1080
3. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572 (Erratum in: JAMA 2003; 290:197.)
4. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
5. Klag M.J., Whelton P.K., Randall B.L., Neaton J.D., Brancati F.L., Ford C.E., et al. Blood pressure and end-stage renal disease in men. N Engl J Med 334 (1996) 13-18
6. Ravid M., Lang R., Rachmani R., and Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 156 (1996) 286-289
7. Parving H.H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., and Arner P. for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001) 870-878
8. Nelson R.G., Bennett P.H., Beck G.J., Tan M., Knowler W.C., Mitch W.E., et al. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med 335 (1996) 1636-1642
9. Gaede P., Tarnow L., Vedel P., Parving H.H., and Pedersen O. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant 19 (2004) 2784-2788
10. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
11. Warram J.H., Scott L.J., Hanna L.S., Wantman M., Cohen S.E., Laffel L.M., et al. Progression of microalbuminuria to proteinuria in type 1 diabetes: nonlinear relationship with hyperglycemia. Diabetes 49 (2000) 94-100
12. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 321 (2000) 405-412
13. Nosadini R., Velussi M., Brocco E., Bruseghin M., Abaterusso C., Saller A., et al. Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. Diabetes 49 (2000) 476-484
14. Nosadini R., and Tonolo G. Blood glucose and lipid control as risk factors in the progression of renal damage in type 2 diabetes. J Nephrol 16 S7 (2003) S42-S47
15. 51Cr-EDTA provides a precise and convenient technique for measurement of glomerular filtration rate in diabetic humans. J Am Soc Nephrol 7 (1996) 118-127
16. Mangili R., DeFerrari G., DiMario U., Giampietro O., Navalesi R., Nosadini R., et al. Prevalence of hypertension and microalbuminuria in adult type I diabetic patients without renal failure in Italy. Validation of screening techniques to detect microalbuminuria. Acta Diabetologica 29 (1992) 156-166
17. DuBois D., and DuBois E.F. A formula to estimate the approximate surface area if height and weight be known. Arch Int Med 17 (1916) 863-871
18. Davidian M., and Giltinan D.M. Nonlinear models for repeated measurement data (1995), Chapman & Hall, London
19. Pinheiro J.C., and Bates D.M. Mixed-effects models in sand S-plus (2000), Springer, New York
20. Hansson L., Lindholm L.H., Niskanen L., Lanke J., Hedner T., Niklason A., et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353 (1999) 611-616
21. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., and Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 3 (2000) 145-153 [Erratum in: N Engl J Med 2000; 342:1376; N Engl J Med 2000; 342:748]
22. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
23. Gress T.W., Nieto F.J., Shahar E., Wofford M.R., and Brancati F.L. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 342 (2000) 905-912
24. The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 288 (2002) 2981-2997
25. Appel L.J. The verdict from ALLHAT-thiazide diuretics are the preferred initial therapy for hypertension. JAMA 288 (2002) 3039-3042
26. Gaede P., Vedel P., Parving H.H., and Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 353 (1999) 617-622